These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 6967199)
1. Indomethacin-mediated enhancement of lymphocyte response to mitogens; in treated and untreated Hodgkin's disease and non-Hodgkin's lymphoma. Han T; Winnicki MS N Y State J Med; 1980 Jun; 80(7 Pt 1):1070-5. PubMed ID: 6967199 [No Abstract] [Full Text] [Related]
2. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. Fisher RI; Bostick-Bruton F J Immunol; 1982 Oct; 129(4):1770-4. PubMed ID: 6980949 [TBL] [Abstract][Full Text] [Related]
3. Immune status of untreated patients with Hodgkin's disease and prognosis. Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640 [TBL] [Abstract][Full Text] [Related]
4. [Lymphoid depletion type 4 Hodgkin disease. Anatomoclinical review of 35 cases]. Eghbali H; Pétorin C; de Mascarel I; Trojani M; Hoerni-Simon G; Soubeyran P; Hoerni B Bull Cancer; 1994 Oct; 81(10):866-70. PubMed ID: 7734769 [TBL] [Abstract][Full Text] [Related]
5. Peripheral blood lymphocyte response to recombinant and non-recombinant interleukin 2 in previously treated patients with Hodgkin's disease, long-time off-therapy. Mantovani G; Coiana A; Massidda A; Locci F; Loy M; Piludu G; Piras MC; Macciò A; Del Giacco GS Eur J Haematol; 1987 Feb; 38(2):179-86. PubMed ID: 3496236 [TBL] [Abstract][Full Text] [Related]
6. Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin's disease. Damle RN; Advani SH; Gangal SG Cancer Immunol Immunother; 1991; 34(3):205-10. PubMed ID: 1756538 [TBL] [Abstract][Full Text] [Related]
7. Impaired proliferative response and low interleukin-2 production in patients with lymphoma. Musatti CC; Yasaka K; Santos LM Braz J Med Biol Res; 1987; 20(3-4):351-62. PubMed ID: 3502537 [TBL] [Abstract][Full Text] [Related]
8. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918 [TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease. Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972 [TBL] [Abstract][Full Text] [Related]
12. Lymphocyte response to pokeweed mitogen in Hodgkin's disease. Cohnen G; König E; Augener W; Brittinger G Biomedicine; 1973 Jun; 19(6):239-43. PubMed ID: 4752298 [No Abstract] [Full Text] [Related]
13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
14. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease. Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562 [TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181 [TBL] [Abstract][Full Text] [Related]
16. Nodular lymphocyte predominant Hodgkin's lymphoma. Siddiqui N; Al-Diab AI Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298 [TBL] [Abstract][Full Text] [Related]
17. Malignant lymphoma in western Ethiopia. Getachew A East Afr Med J; 2001 Aug; 78(8):402-4. PubMed ID: 11921560 [TBL] [Abstract][Full Text] [Related]
18. [The effect of phytohemagglutinin on lymphocytes in Hodgkin's disease]. Eggerth G; Kühböck J; Pokorny D Wien Z Inn Med; 1969; 50(7):314-9. PubMed ID: 5380683 [No Abstract] [Full Text] [Related]
19. Monocyte function in Hodgkin's disease. Holm G; Björkholm M; Johansson B; Mellstedt H; Lindemalm C Clin Exp Immunol; 1982 Jan; 47(1):162-8. PubMed ID: 7094420 [TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]